New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
12:00 EDTBDSIBioDelivery Sciences price target raised to $13 from $9 at Ladenburg
Ladenburg raised its price target on shares of BioDelivery Sciences to $13 from $9 following positive top-line data for one of its BEMA buprenorphine Phase III trials. Ladenburg believes these results portend a high probability for positive results from another ongoing Phase 3 study of the drug in another set of patients and the firm maintains a Buy rating on shares.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
September 8, 2014
08:52 EDTBDSIBioDelivery Sciences price target raised to $28 from $20 at Summer Street
Summer Street raised its price target for BioDelivery Sciences shares to $28 saying it left the company's analyst day on Friday incrementally more positive. The firm believes its sales estimates for Bunavail and BEMA Buprenorphine may prove to be conservative and reiterates a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use